GlassScriptPhysician profile
Ronnie Claiborne
NPI 1578503256
$12,700.85
in general payments reported to CMS, 2019-2025
57 companies · $1,412 in 2025
The $1,412 reported for 2025 was more than what 94% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,841 · 2020: $1,585 · 2021: $1,961 · 2022: $2,356 · 2023: $1,930 · 2024: $1,616 · 2025: $1,412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,772 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,771.73 |
| Education | $185.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,149.35 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,091.41 | 2019-2025 | Farxiga, Breztri, Andexxa |
| Merck Sharp & Dohme LLC | $1,070.01 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $601.51 | 2020-2025 | Caplyta |
| Novo Nordisk INC | $522.95 | 2019-2025 | Ozempic, Rybelsus |
| Lundbeck LLC | $497.34 | 2020-2025 | Rexulti, Abilify Asimtufii |
| Abbvie INC. | $462.82 | 2019-2025 | Ubrelvy, Qulipta, Creon |
| Lilly USA, LLC | $447.08 | 2019-2025 | Mounjaro, Zepbound |
| Corcept Therapeutics | $436.72 | 2022-2024 | Korlym |
| Glaxosmithkline, LLC. | $434.34 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $430.32 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $406.47 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $353.25 | 2019-2024 | |
| Aimmune Therapeutics, INC. | $350.08 | 2024-2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $328.09 | 2019-2024 | Xifaxan |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronnie Claiborne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.